文献速递膀胱癌与上尿路尿路上皮癌

年龄与非肌层浸润性膀胱癌的关联:为流行病学差异寻找生物学基础

Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?
PubMed 文献 · Eur Urol Oncol · 2024-02-01

研究利用SEER-Medicare数据库(n=32 225)和UROMOL队列(n=834)分析非肌层浸润性膀胱癌的年龄差异,发现高龄与更差的肿瘤学结局相关,且转录组和基因组层面存在年龄相关分子生物学差异,提示肿瘤生物学贡献于观察到的结局差异。

要点

  • SEER-Medicare队列中,年龄≥81岁与更高的复发、进展和膀胱癌特异性死亡风险相关。
  • UROMOL队列中,UROMOL2021转录组2a类在高龄患者中更常见(≥76岁34.0% vs ≤65岁21.6%)。
  • UROMOL2021基因组3类在≥76岁患者中观察更频繁(4.9% vs 24.2%)。

核心结论

  • 在SEER-Medicare非肌层浸润性膀胱癌患者中,高龄与更差的肿瘤学结局相关。
  • 这些结果反映了转录组和基因组层面观察到的年龄相关分子生物学差异,进一步证明固有肿瘤生物学贡献于NMIBC结局差异。

研究设计与样本

  • 使用SEER-Medicare数据识别2005年至2017年间临床分期Ta、Tis和T1的NMIBC患者(n=32 225)。
  • 使用UROMOL队列(n=834)评估转录组、基因组和空间蛋白质组领域的年龄差异。
  • SEER-Medicare数据采用多变量竞争风险回归分析年龄与复发、进展和膀胱癌特异性死亡率(BCSM)的关联。
  • UROMOL队列采用多变量一般线性模型和多项逻辑回归评估年龄与肿瘤生物学的关联。

主要发现

  • SEER-Medicare队列中,66-70岁、71-80岁和≥81岁患者的5年复发率分别为55.2%、57.4%和58.9%。
  • SEER-Medicare队列中,66-70岁、71-80岁和≥81岁患者的5年进展率分别为25.6%、29.2%和36.9%。
  • SEER-Medicare队列中,66-70岁、71-80岁和≥81岁患者的5年BCSM率分别为3.9%、5.8%和11.8%。
  • 多变量调整后,年龄≥81岁与更高的复发风险(HR 1.07,95%CI 1.03-1.12;p=0.001)、进展风险(HR 1.32,p<0.001)和BCSM风险(HR 2.58,p<0.001)相关。
  • UROMOL2021转录组2a类在高龄患者中最常见(≥76岁34.0% vs ≤65岁21.6%;p=0.004),多变量分析确认(RR 3.86,p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性包括复发和进展的定义,可能导致真实率的低估或高估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age disparity in patients with non-muscle-invasive bladder cancer (NMIBC) exists. Whether this is due to differences in adequate cancer care or tumour biology is unclear. OBJECTIVE: To investigate age disparities in NMIBC using the Surveillance, Epidemiology, and End Results (SEER)-Medicare and UROMOL datasets. DESIGN, SETTING, AND PARTICIPANTS: The SEER-Medicare data were used to identify patients with clinical stage Ta, Tis, and T1 NMIBC between 2005 and 2017 (n = 32 225). Using the UROMOL cohort (n = 834), age disparities across transcriptomic, genomic, and spatial proteomic domains were assessed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For the SEER-Medicare data, multivariable competing-risk regression was used to examine the association between age and recurrence, progression, and bladder cancer-specific mortality (BCSM). For the UROMOL cohort, multivariable general linear model and multinomial logistic regression were performed to evaluate the association between age and tumour biology. RESULTS AND LIMITATIONS: An analysis of the SEER-Medicare cohort revealed 5-yr recurrence rates of 55.2%, 57.4%, and 58.9%; 5-yr progression rates of 25.6%, 29.2%, and 36.9%; and 5-yr BCSM rates of 3.9%, 5.8%, and 11.8% in patients aged 66-70, 71-80, and ≥81 yr, respectively. After multivariable adjustment, age ≥81 yr was associated with a higher risk of recurrence (hazard ratio [HR] 1.07, 95% confidence interval [CI] 1.03-1.12; p = 0.001), progression (HR 1.32, p < 0.001), and BCSM (HR 2.58, p < 0.001). UROMOL2021 transcriptomic class 2a was most frequently observed in patients with advanced age (34.0% in ≥76 yr vs 21.6% in ≤65 yr; p = 0.004), a finding confirmed on multivariable analysis (risk ratio [RR] 3.86, p = 0.002). UROMOL2021 genomic class 3 was observed more frequently in patients aged ≥76 yr (4.9% vs 24.2%; p = 0.001). Limitations include the definitions used for recurrence and progression, which may lead to under- or overestimation of true rates. CONCLUSIONS: Among SEER-Medicare patients with NMIBC, advanced age is associated with inferior oncological outcomes. These results reflect age-related molecular biological differences observed across transcriptomic and genomic domains, providing further evidence that innate tumour biology contributes to observed disparities in NMIBC outcomes. PATIENT SUMMARY: Older patients with non-muscle-invasive bladder cancer have worse oncological outcomes than younger patients. Some of this age disparity may be due to differences in tumour biology.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lobo N, Duan Z, Sood A, et al. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? Eur Urol Oncol. 2024. PMID: 38302322. doi:10.1016/j.euo.2024.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。